Datavault AI Q2 2025 Recognized Revenue of $1.7M, Reflecting 467% Year-Over-Year Growth and Booked a $2.5M Licensing Deal with Nyiax
Furthermore, Datavault AI secured $2.5 million in patent licensing bookings not included in Q2 results, stemming from its cross-licensing agreement with Nyiax Inc. This agreement provides critical access to the NASDAQ financial framework, fostering the launch of three token exchanges, which are expected to be recognized in future periods and further bolster revenue visibility. The license will be paid in Nyiax stock to strengthen the partnership between the companies. These strategic achievements in the second quarter of 2025 underscore the operational and financial momentum under the new leadership team.
Since January 7, 2025, Datavault AI has executed on the integration of Datavault Holdings, WiSA, CSI, and partnerships with IBM Watsonx, Nyiax, GFT Rewards, and Turner Global Media. These initiatives are driving revenue acceleration toward a $25 million run rate by year-end and positioning the company for a $40–$50 million revenue target in 2026.
Seminal Event in the United States Regulatory Environment and the Role of Intellectual Property Expansion at Datavault AI
On July 21, the company announced Genius Act Signed into Law Validating Growing Datavault AI Patent Portfolio.
Top U.S. Banks have been identified as patent infringers by third-party legal counsel involving the Datavault AI patented exchange and Web 3.0 technologies, which are designed to monetize data, real-world assets, and precious earth elements. An extensive financial and technological expert review has been conducted, along with detailed claim charts. The company has retained top-tier IP litigation funding and counsel, Fish Richardson LLP, to pursue licensing settlements or initiate litigation-based licensing activities immediately.
Key holdings and claims include secure data monetization, AI-driven valuation, and acoustic innovations for defense and consumer applications, fostering trust through Web 3.0 anchoring, scalability, and cyber-secure compliance in high-stakes sectors like defense, biotech, and finance.
This aligns with Datavault AI's strategic plan, as evidenced by press releases announcing partnerships (e.g., with Burke Products for defense applications on July 22, 2025; IBM Partner Plus integration on March 2025; and FEC approval for political campaigns on December 21, 2022), market expansions (e.g., Elements Exchange for tokenized real-world assets on July 17, 2025), and revenue projections (e.g., $50M target by 2026 via tokenized RWAs).
Datavault AI's expanding intellectual property (IP) portfolio now includes 72 patent assets (30 issued, 10 allowed, 32+ pending), 14 issued trademarks, 11 allowed trademarks, and 3 pending trademarks.
Strategic Initiatives for Q3 2025
Launch new International Elements Exchange, International NIL Exchange, and American Politics Exchange, leveraging Datavault's Web3 infrastructure and high-performance computing backbone.
Advance commercialization of IBM-powered AI agents within Datavault's platform.
Complete 2025 strategic acquisitions in Acoustic and Data divisions, expanding core growth markets.
Execute plans for supercomputing and AI development strategy to support long-term scale.
Provide update on API Media integration, revenue impact and next steps, following selection by a leading event company for acquisition based on technological, market and timing advantages assembled by management.
Q2 Highlights
Datavault AI Debuts Enterprise Commercialization for AI Agents Built With IBM watsonx.ai for AI-Powered Data Monetization
The Carbon Credit Tokenization Patent, issued Friday June 20th, Pioneers a Scalable, Stablecoin AI-Driven Blockchain Platform for Generating, Trading, and Monetizing Carbon Credits
Strategic Licensing Agreement with GFT Rewards for ADIO-Enabled Mobile Rewards
NFL Alumni Health Taps Datavault AI's ADIO® for Health-Focused and Interactive Web 3.0 Activations
Acquisition Activity and Systems Integrations
Completed integration of WiSA's wireless audio IP into Datavault's data monetization platform, extending opportunities in audio, NFT, and media verticals.
Completed integration of CompuSystems event registration and data system with Datavault AI's systems.
Completed Integration of ADIO into the NYAIX Marketing Management System.
Finalized API Media Acquisition Plan and Integration Schedule.
Strategic Financing & Growth Fuel
The company believes revenue growth and increased cash flows from sales of licensed technologies, product lines, and acquired revenue streams, with a focus on annual recurring revenues and automated transactional revenues on our patented Information Data Exchange technology stack, will drive sustainable growth as it moves toward optimized break-even points.
Management Commentary
'These achievements reflect our focused execution on integrating acquisitions, innovating with partners like IBM, and scaling revenue in the booming AI data economy,' said Nate Bradley, CEO of Datavault AI. 'With new funding secured, a strengthened IP portfolio, and multiple platform launches ahead, we are on track to achieve a $25M run rate this year and deliver on our $40M-$50M revenue target in 2026.'
Investor Conference Call on August 20, 2025
Datavault will host an investor call to review business progress and discuss its key strategic priorities:
Date: Wednesday, August 20, 2025
Time: 9:00 AM ET
Webcast & Presentation: https://ir.datavaultsite.com/news-events/ir-calendar
Dial-in: 1-833-366-1124 (US), 1-412-317-0702 (Intl)
Replay Available: Webcast replay will be available approximately one hour after the end of the call and will be available for 90 days, at the above webcast link. A telephonic replay will be available through August 26, 2025, and may be accessed by calling 1-877-344-7529 (US) or 1-412-317-0088 (Intl) and using access code 3269980.
About Datavault AI
Datavault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI's technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Words such as "expect," "will," "anticipates," "continues" and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Such forward-looking statements, including statements herein regarding our business opportunities and prospects, strategy, future revenue expectations, licensing initiatives, patent initiatives as well as the successful implementation of the patented technologies, are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: our ability to successfully utilize all intellectual property that has been issued and granted Notices of Allowance; risks regarding our ability to utilize the assets we acquire to successfully grow our market share; risks regarding our ability to open up new revenue streams as a result of the various patents mentioned in this press release; our current liquidity position and the need to obtain additional financing to support ongoing operations; general market, economic and other conditions; our ability to continue as a going concern; our ability to maintain the listing of our common stock on Nasdaq; our ability to manage costs and execute on our operational and budget plans; our ability to achieve our financial goals; the degree to which our licensees implement our technologies into their products, if at all; the timeline to any such implementation; risks related to technology innovation and intellectual property, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this communication based on new information, future events, or otherwise, except as required by law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Modivcare Enters into Comprehensive Restructuring Agreement to Strengthen its Future, Reduce Debt and Inject Capital
DENVER--(BUSINESS WIRE)--Modivcare Inc. (the 'Company' or 'Modivcare') (Nasdaq: MODV), a technology-enabled healthcare services company providing a platform of integrated supportive care solutions focused on improving health outcomes, today announced that it has taken necessary and decisive action intended to strengthen its financial foundation while continuing to provide access to care, reduce costs, and improve outcomes for clients and members nationwide. Modivcare has filed for voluntary Chapter 11 protection in the U.S. Bankruptcy Court for the Southern District of Texas to implement a comprehensive restructuring transaction with the support of a supermajority of its key stakeholders. Through this process, Modivcare intends to build a stronger, sustainable organization, positioned for growth and well-equipped to meet the critical needs of members across its non-emergency medical transportation, personal care services and remote patient monitoring service lines. 'Modivcare sits at the center of the preventive healthcare ecosystem,' said Heath Sampson, Chief Executive Officer and President of Modivcare. 'This recapitalization strengthens our balance sheet and allows Modivcare to accelerate our investment in innovation by combining technology and data with high-touch member engagement. As the connector to care, our seamlessly connected platform improves access, quality and cost for payors, providers and facilities, while positioning us to lead the future of coordinated care.' More than 90% of First Lien Lenders and more than 70% of Second Lien Lenders have entered into a Restructuring Support Agreement ('RSA') with the Company. Those lenders have committed to support the Company throughout this process and have agreed to provide $100 million in 'debtor-in-possession' ('DIP') financing to finance the restructuring process and to support ongoing operations during this expedited bankruptcy process. Upon the closing of the DIP loan, Modivcare will have liquidity in excess of $100 million. The restructuring will reduce the Company's total outstanding funded debt obligations by approximately $1.1 billion (which is more than 85% of its outstanding funded debt obligations) and will meaningfully reduce the Company's annual cash interest and transition ownership to a group of seasoned and well-funded investors who are committed to Modivcare's success. All of Modivcare's service lines will continue to operate in the ordinary course, and we expect no interruption or change in access to care and a continued focus on operational excellence. Modivcare intends to close this transaction quickly by exiting the restructuring process early in the fourth quarter of 2025. Modivcare remains committed to providing excellent service to clients and their members. The Company has filed customary motions that, once approved, will allow Modivcare to meet obligations to clients and critical vendors, including transportation providers, and pay employee wages and benefits as usual. For more information about the Company's Chapter 11 case, including claims information, please visit or contact Verita, the Company's noticing and claims agent, at +1 (888) 733-1521 for U.S. and Canada or +1 (310) 751-2636 for international. Modivcare is advised by Latham & Watkins LLP, Hunton Andrews Kurth LLP, Moelis & Company LLC, and FTI Consulting. The First Lien Agent, the First Lien Lenders and the Second Lien Noteholders executing the RSA are advised by Paul Hastings LLP and Lazard. Cautionary Note Regarding Forward-Looking Statements Statements contained in this release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are identified generally by the use of the terms 'intended', 'expected', 'estimates', 'will', and 'anticipates', and similar words or expressions indicating possible future expectations, events or actions. Forward-looking statements include statements regarding the Company's expectation about its ability to continue operating its business, fulfill its mission, make payments and meet obligations, and the Company's ability to implement the restructuring pursuant to the Chapter 11 cases, including the timetable of completing such transaction, if at all. Forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company's business and its industry, and are not guarantees of future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond the Company's ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein. The Company has provided additional information about the risks facing its business and the Company in its most recent annual report on Form 10-K, and in its subsequent periodic and current reports on Forms 10-Q and 8-K, filed by it with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made and are expressly qualified in their entirety by the cautionary statements set forth herein and in the periodic and current reports filed with the Securities and Exchange Commission identified above, which you should read in their entirety before making an investment decision with respect to the Company's securities. The Company undertakes no obligation to update or revise any forward-looking statements contained in this report, whether as a result of new information, future events or otherwise, except as required by applicable law. About Modivcare Modivcare Inc. ("Modivcare" or the "Company") is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their members. The Company's value-based solutions address the social determinants of health (SDoH) by connecting members to essential care services. By doing so, Modivcare helps health plans manage risks, reduce costs, and improve health outcomes. Modivcare is a provider of non-emergency medical transportation (NEMT), personal care services (PCS), and remote patient monitoring solutions (RPM). To learn more about Modivcare, please visit
CNBC
21 minutes ago
- CNBC
Microsoft's gutting of discounts for some clients likely baked into guidance, analyst says
Microsoft said last week that it plans to stop providing discounts on enterprise purchases of its Microsoft 365 productivity software subscriptions and other cloud applications. Since the announcement, analysts have published estimates on how much more customers will end up paying. But for investors trying to figure out what it all means to Microsoft's financials, analysts at UBS said the change is already factored into guidance. "In our view, it is safe to assume that the impact of the pricing change" was included in Microsoft's forecast, the analysts wrote in a report late Tuesday. They have a buy rating on the stock. Microsoft didn't respond to a request for comment. Microsoft's disclosure, on Aug. 12, came two weeks after the software company, it its fiscal fourth-quarter earnings report, issued a forecast that included double-digit year-over-year revenue growth for the new fiscal year. The shares rose 4% after the report. Microsoft said in its blog post announcing the pricing change that, "This update builds on the consistent pricing model already in place for services like Azure and reflects our ongoing commitment to greater transparency and alignment across all purchasing channels." The change applies to companies with enough employees to get them into price levels known as A, B, C and D. It goes into effect when organizations sign up for new services or renew existing agreements, beginning on Nov. 1. Jay Cuthrell, product chief at Microsoft partner NexusTek, said customers will see price hikes of 6% to 12%. Partners are estimating an impact as low as as 3% and as high as 14%, UBS analysts wrote. Microsoft 365 commercial seat growth, a measurement of the number of licenses that clients buy for their workers, has been under 10% since 2023. Microsoft is aiming to generate more revenue per seat by selling Copilot add-ons and moving some users to more expensive plans. Expanding that part of the business is crucial. Most of Microsoft's $128.5 billion in fiscal 2025 operating profit came from the Productivity and Business Processes unit, and about 73% of the revenue in that segment was from Microsoft 365 commercial products and cloud services. Some customers could agree to pay Microsoft more to keep using the applications rather than moving to alternative services, said Adam Mansfield, practice lead at advisory firm UpperEdge. They may also lower their commitments to Microsoft in other areas, such as Azure cloud infrastructure, Mansfield said. One way companies could potentially pay lower prices with the disappearance of discounts is by buying through cloud resellers instead of going direct, said Nathan Taylor, a senior vice president at Sourcepass, an IT service provider that caters to small businesses. Sourcepass hasn't gotten many leads as a result of Microsoft's change yet, Taylor said. "It takes a while for that information to disseminate to the industry at large," he said. Microsoft shares are up 20% this year, while the Nasdaq has gained about 10%.
Yahoo
43 minutes ago
- Yahoo
NUTEX HEALTH PROVIDES FINANCIAL REPORTING UPDATE
HOUSTON, Aug. 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today disclosed non-reliance on its (i) unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2025 contained in the Form 10-Q for the period ended March 31, 2025 (the "Original Form 10-Q") and its (ii) audited consolidated financial statements as of and for the years ended December 31, 2024 and 2023 contained in the Form 10-K for the year ended December 31, 2024 and 2023 (the "Original Form 10-K") (collectively, the "Previously Issued Financial Statements"). As noted in the 8-K filed today, on August 20, 2025, the Company, in consultation with the Audit Committee of the Board of Directors and its Auditor, reached a determination that the Company's Previously Issued Financial Statements should no longer be relied upon solely due to changes to the non-cash classification of obligations related to under construction and ramping hospitals from equity to liability in accordance with the classification criteria in ASC 718, Compensation - Stock Compensation, and ASC 480, Distinguishing Liabilities from Equity. For additional clarity, this non-reliance is anticipated to be non-cash adjustments that are not due to issues related to collections or Independent Dispute Resolutions (arbitration) related activities. The Company has determined that it is appropriate to correct the classification in the Company's Previously Issued Financial Statements by amending its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the "First Quarter 2025 Form 10-Q/A"), and its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K/A"). The Company expects that any adjustments related to the treatment of these obligations will be non-cash and have no effect on key financial statement line items such as its revenue, gross profit, liquidity, working capital, short-term and long-term debt, operating cash flow, adjusted EBITDA or number of patient visits. Preliminary Financial Information Prior to the filing of the First Quarter 2025 Form 10-Q/A, the 2024 Form 10-K/A, and the full financial results for the period ended June 30, 2025, the Company has provided below select preliminary unaudited financial results for the three and six months ended June 30, 2025, which reflect management's current views with respect to the Company's financial results. These preliminary results remain subject to the completion of normal quarter-end and fiscal-end accounting procedures and closing adjustments. Financial highlights for the three months ended June 30, 2025: Total revenue was $244.0 million for the three months ended June 30, 2025 as compared to total revenue of $76.1 million for the same period in 2024, an increase of 220.7%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 203.2% in 2025 compared to 2024. Gross profit was $124.8 million, or 51.1% of total revenue, for the three months ended June 30, 2025 as compared to gross profit of $22.6 million, or 29.7% of total revenue, for the same period in 2024. Total visits at the Hospital Division were 45,573 for the three months ended June 30, 2025, as compared to 41,208 for the same period in 2024, an increase of 4,365 or 10.6%. Visits at mature hospitals increased by 0.6% in the three months ended June 30, 2025 as compared to the same period in 2024. For the three months ended June 30, 2025, the Company collected $175 million in cash, the highest collection amount for any quarter. Adjusted EBITDA was $71.6 million for the three months ended June 30, 2025 as compared to $6.8 million for the same period in 2024. Operating cash flow was $27.1 million for the three months ended June 30, 2025 as compared to $13.3 million for the same period in 2024. Financial highlights as of and for the six months ended June 30, 2025: Total revenue was $455.8 million for the six months ended June 30, 2025, as compared to total revenue of $143.5 million for the same period in 2024, an increase of 217.5%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 195.2% in 2025 compared to 2024. Gross profit was $243.1 million, or 53.3% of total revenue, for the six months ended June 30, 2025, as compared to gross profit of $32.7 million, or 22.8% of total revenue, for the same period in 2024. Total visits at the Hospital Division were 93,842 for the six months ended June 30, 2025, as compared to 81,276 for the same period in 2024, an increase of 12,566 or 15.5%. Visits at mature hospitals increased by 3.0% in the six months ended June 30, 2025, as compared to the same period in 2024. For the six months ended June 30, 2025, the Company collected $311 million in cash, the highest collection amount for the first two quarters of any year. Adjusted EBITDA was $144.4 million for the six months ended June 30, 2025, as compared to $6.4 million for the same period in 2024. Operating cash flow was $78.1 million for the six months ended June 30, 2025, as compared to $16.3 million for the same period in 2024. As of June 30, 2025, the Company had total assets of $854.8 million, including cash of $96.4 million and accounts receivable of $349.2 million. Current portion of long-term debt and long-term debt was $15.0 million and $20.5 million, respectively, as of June 30, 2025. Additional Information The Company will host a shareholder update call to be scheduled for Monday August 25, 2025 at 10:30 am Eastern Time, where it will discuss preliminary second quarter financials as well as other topics relevant to the Company, as also described in its Form 8-K filed on the date hereof. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website. Notification of Delinquency with Nasdaq On August 20, 2025, Nutex received a delinquency notification letter from Nasdaq, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025. While this notice does not immediately affect the listing of Nutex's securities, the company risks delisting if it does not resolve the issue by submitting a compliance plan to Nasdaq by October 20, 2025, 60 days from August 20, 2025. If accepted, Nutex could have until February 10, 2026, to comply. Nutex is currently working to complete its delayed financial filings. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations. Through our Management Services Organization, we provide management, administrative and other support services to our affiliated hospitals and physician groups. Forward-Looking Statements This Press Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, statements regarding future changes in laws or regulations applicable to our operations, in particular, changes to the regulations promulgated under the No Surprises Act, any statements about our business, financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, or otherwise, and our future liquidity, including cash flows; any statements regarding the timing of the filing of the amendments to our prior SEC filings and 10-Q for the second quarter of 2025; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; or strategic transactions; any statements regarding management's view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as "anticipate," "could," "can," "may," "might," "potential," "predict," "should," "estimate," "expect," "project," "believe," "think," "plan," "envision," "intend," "continue," "target," "seek," "contemplate," "budgeted," "will," "would" and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described under, but not limited to, the heading "Item 1A. Risk Factors" included in the Annual Report of Nutex Health Inc. on Form 10-K for the year ended December 31, 2024 and other filings of the Company with the United States Securities and Exchange Commission. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes and results to differ materially from those indicated by such statements. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements. View original content: SOURCE Nutex Health, Inc. Sign in to access your portfolio
